COMPASS THERAPEUTICS, INC. Deferred Tax Assets, Net of Valuation Allowance
COMPASS THERAPEUTICS, INC. (CMPX) had Deferred Tax Assets, Net of Valuation Allowance of $2.56 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsNet · last filed 2026-03-05
- 2025-12-31: Deferred Tax Assets, Net of Valuation Allowance $2.56M.
- 2024-12-31: Deferred Tax Assets, Net of Valuation Allowance $1.90M.
- 2023-12-31: Deferred Tax Assets, Net of Valuation Allowance $485.00K.
- 2022-12-31: Deferred Tax Assets, Net of Valuation Allowance $809.00K.
| Period end | Deferred Tax Assets, Net of Valuation Allowance |
|---|---|
| 2025-12-31 | $2.56M 10-K · filed 2026-03-05 |
| 2024-12-31 | $1.90M 10-K · filed 2026-03-05 |
| 2023-12-31 | $485.00K 10-K · filed 2025-02-27 |
| 2022-12-31 | $809.00K 10-K · filed 2024-03-21 |
| 2021-12-31 | $1.17M 10-K · filed 2023-03-15 |
| 2020-12-31 | $76.00K 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |